May 16 (UPI) -- The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in patients beginning to show cognitive decline.
Fujirebio Diagnostics, a firm dedicated to developing medical diagnostic products, has been cleared by the FDA to begin marketing the test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio.
"Nearly 7 million Americans are living with Alzheimer's disease and this number is projected to rise to nearly 13 million," said Dr. Michelle Tarver, the director of the Center for Devices and Radiological Health.
"Today's clearance is an important step for Alzheimer's disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease."
Related
